- Home
- HIO vs VRXA Comparison
HIO vs VRXA Comparison
Compare HIO & VRXA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HIO | VRXA |
|---|---|---|
| Founded | 1993 | N/A |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 348.1M | 390.3M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | HIO | VRXA |
|---|---|---|
| Price | $3.62 | $2.05 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 306.8K | ★ 1.2M |
| Earning Date | 01-01-0001 | N/A |
| Dividend Yield | ★ 10.33% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.52 | $1.70 |
| 52 Week High | $4.05 | $4.50 |
Technical Indicators
Market Signals| Indicator | HIO | VRXA |
|---|---|---|
| Relative Strength Index (RSI) | 48.16 | 29.57 |
| Support Level | $3.62 | $1.94 |
| Resistance Level | $3.68 | $3.49 |
| Average True Range (ATR) | 0.03 | 0.38 |
| MACD | -0.00 | 0.04 |
| Stochastic Oscillator | 35.71 | 18.26 |
Price Performance
Historical ComparisonAbout HIO Western Asset High Income Opportunity Fund Inc.
Western Asset High Income Oppor Fd Inc is a diversified closed-end management investment company. The company's primary objective is to seek high current income and the secondary objective is capital appreciation. It invests a majority of its net assets in high-yield corporate debt securities and the rest in common stock equivalents, including options, warrants, and rights. The company invests in securities of companies from various sectors such as energy, technology, utilities, industrials, communications, finance, and capital goods among others.
About VRXA Veraxa Biotech AG Ordinary Shares
Veraxa Biotech Holding AG focus on antibody therapies in medicine. The Company is an oncology-focused biotechnology Company with a clinical program in acute myeloid leukemia and two proprietary platform technologies that enable the development of new generations of antibody drug conjugates (ADC's) and T cell engagers. The Company operates in one reportable segment, focused on the research and development of products for the aging population.